Raed Ibraheim, Ph.D
About Raed Ibraheim, Ph.D
Raed Ibraheim, Ph.D, is a scientist at Tessera Therapeutics, specializing in gene writing and the GMP manufacturing of clinical-grade AAV vectors. He has a strong academic background with a Ph.D. in CRISPR genome editing and has published research in notable scientific journals.
Work at Tessera Therapeutics
Raed Ibraheim has been employed as a Scientist at Tessera Therapeutics since 2021. In this role, he leads a team of scientists focused on 'Gene Writing'. His work involves characterizing the activity and off-target editing of novel Cas9 nucleases. Ibraheim has contributed to the company's research initiatives, including presenting a poster on the correction of the Human Wilson’s Disease mutation using RNA Gene Writers at the American Society of Gene and Cell Therapy 27th Annual Meeting.
Education and Expertise
Raed Ibraheim holds a Doctor of Philosophy (Ph.D.) from UMass Chan Medical School, where he studied CRISPR genome editing and gene therapy from 2015 to 2020. He also earned a Bachelor of Medicine, Bachelor of Surgery (MB ChB) from Mustansiriyah Medical College in Baghdad, Iraq, from 2006 to 2008. Additionally, he obtained a Bachelor's degree in Biology from Bard College, studying there from 2009 to 2013. His expertise includes GMP manufacturing of clinical-grade AAV vectors and engineering AAV.Cas9 vectors for various gene editing applications.
Previous Positions and Experience
Before joining Tessera Therapeutics, Raed Ibraheim held several academic positions. He worked as Faculty (Citizen Science) at Bard College for seven months in 2019. He was a Ph.D. Candidate and Ruth L. Kirschstein NRSA Fellow at the University of Massachusetts Medical School from 2015 to 2020. Ibraheim also served as a Research Assistant at Bard College in two separate roles, from 2010 to 2011 and from 2012 to 2013, and briefly at the Icahn School of Medicine at Mount Sinai in 2010.
Publications and Research Contributions
Raed Ibraheim has published first-author papers in several prestigious journals, including Nature Communications, Genome Biology, and Human Gene Therapy. His research primarily focuses on gene editing technologies, particularly in the context of AAV.Cas9 vectors. His contributions to the field of gene therapy and genome editing are recognized through his publications and presentations at significant scientific meetings.